Biomedical Engineering Seminar - 26 May 2015
May 26, 2015
from 12:45 PM to 01:45 PM
|Where||Ludwig/Jenner Seminar Room, Rm 678.00.59A, Old Road Campus Research Building, Headington, Oxford|
|Contact Name||Professors Robin Cleveland and Eleanor Stride|
|Contact Phone||+44(0)1865 617737/617747|
|Add event to calendar||
Liver cancer is the third leading cause of cancer death, with over 700,000 globally per year. Loco-regional treatments are finding wide-spread use in the treatment of liver tumours in an attempt to specifically target malignant tissues and spare the patient of undesired side effects. Drug-eluting Beads (DEBs) composed of biomedical polymers provide for an image-guided minimally-invasive intrahepatic administration designed to block the blood supply to the tumour, depriving it of oxygen and nutrients, followed by a controlled and sustained elution of chemotherapeutic agents. This presentation will focus on DC Bead®, the most widely used and studied DEB in the clinic, how it is made, how it is prepared for use in the pharmacy and the benefits it bestows upon both physician and patient as a mainstay therapy in the interventional oncologist’s armoury. There will also be some insight into future developments with the emergence of imageable DEBs capable of being visualised under the X-ray imaging techniques used to conduct interventional procedures.
Andy gained a First Class Combined Honours in Biochemistry & Chemistry and a PhD in Chemistry from Aston University. He spent his early career with ICI working in the area of advanced polymer membranes and subsequently with Johnson & Johnson leading projects in absorbent technologies, which led to granted patents and commercialised products for both companies. Since 1996, Andy has held various R&D roles for Biocompatibles UK Ltd, (now a BTG International Ltd group company), where he is currently the Director of Research & Development in the Innovation function. He specialises in the development of advanced biomedical polymer systems, for instance, to enhance the biocompatibility of implants or to modulate delivery of active agents in the body. These technologies have been applied to novel drug-device combination products for use in interventional therapies in the treatment of cardiovascular disease and cancer.